CIRIUM
6.1.2022 09:21:06 CET | Business Wire | Press release
Aviation analytics firm Cirium, reveals that December was the busiest month in 2021 for flights globally, totaling 2.43 million, however the total number of flights canceled globally between December 24, 2021, and January 3, 2022, was 59,240, some 2.4%.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220105006010/en/
The number of cancelations over this period is the most cancelations in December for the past decade, six times more than the cancelations in 2019 and two and half times more than 2020. A total of 20,500 flights were canceled in the first three days of the new year.
The big four US airlines, including American Airlines, Delta Air Lines, Southwest Airlines and United Airlines, canceled nearly 7,040 flights over this period.
The cancelations being driven by the surging cases of the Omicron variant of COVID-19 and other operational challenges (including winter weather). Airlines rapidly canceled flights due to staff shortages across crew and ground operations.
Pre-Omicron, global flights flown increased 1.5% week-over-week (December 11-17, 2021). However, global flights are now down 5% compared to the week prior, following the impact of Omicron.
There are large variances between the regions, with the US, Europe and North Atlantic down 9-10%, China up 6%, while Asia-Pacific and Middle East are flat.
“Flight disruptions affect airlines and airports differently – it depends on the availability and flexibility of equipment and resources in place to react quickly. Those that plan more conservatively will minimize their operational disruptions. Cirium monitors the level of disruption by measuring completion factor of flights and their on-time performance,” said Jeremy Bowen CEO at Cirium.
“Cirium’s recent On-Time Performance Review shows how some airlines have focused on their operations to reduce the impact on passengers. For example, Delta Air Lines completed 99.8% of their flights from June to December 2021 and All Nippon Airways, the winner of the Global airline category in Cirium’s Review had a completion factor of 99.2%.”
Consideration is given to the carriers with high volumes of flights. For example, American Airlines flew the most flights in 2021 – around 1,850,050 – and still, its flights arrived 80.47% on time. The carrier did have trouble reinstating flight volumes after more than a year of deeply depressed demand yet completed 97.5% of its flights.
Hartsfield-Jackson Atlanta International Airport (ATL), the major hub for Delta Air Lines, was the busiest airport based on departing flights with 336,890 this year. Despite handling the most flights, it ranked 15th in on-time performance of the Top 20 Global airports.
Amsterdam Airport (AMS) was the busiest airport for international flights in 2021, with a total of 123,070 departing flights, however, it didn’t make the Top 20 airport rankings for on-time performance. Airports have experienced many variables this year in deploying comprehensive pandemic protocols, optimizing the reconciliation and collection of fees and services, and optimizing staffing.
Cirium’s On-Time Performance Review is the industry standard for airlines and airports operational performance. Cirium resumed reporting in June 2021, as flight volumes returned, with regular monthly updates that help gauge the industry’s performance in getting passengers from point A to point B, on time. Cirium’s on-time performance analysis is based on flight data from over 600 sources of real-time flight information.
Click here to download the complimentary On-Time Performance Review 2021.
About Cirium
Cirium brings together powerful data and analytics to keep the world moving. Delivering insights, built from decades of experience in the sector, enabling travel companies, aircraft manufacturers, airports, airlines and financial institutions, among others, to make logical and informed decisions which shape the future of travel, growing revenues and enhancing customer experiences. Cirium is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.
For further information please follow Cirium updates on LinkedIn or Twitter or visit www.cirium.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220105006010/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 17:16:00 CEST | Press release
Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor
Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 16:28:00 CEST | Press release
With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f
Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press release
Advanced energy prediction platform adds real-time energy pricing for North American Independent System Operator (ISO) customers, accelerates meters-connected growth. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On th
Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press release
Southwest Airlines, The Economist, and OneFootball among brands recognized at Elevate’26 Customer Experience Summit for setting the standard in mobile-first and AI-centered customer experiences Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading t
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
